Mk-8892    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension3

86. Pulmonary arterial hypertension    [ 1,083 clinical trials,   667 drugs,   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways]
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 1,083 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01934647
(ClinicalTrials.gov)
November 22, 201330/8/2013Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)A Non-randomized, Single-Panel, Open-Label Trial to Study the Safety, Tolerability and Pharmacodynamics of MK-8892 Acute Dosing in Subjects With Moderate to Severe Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: MK-8892Merck Sharp & Dohme Corp.NULLTerminated18 Years70 YearsAll7Phase 1Germany
2NCT01926509
(ClinicalTrials.gov)
November 14, 201319/8/2013Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)A 28-Day Multiple-Dose Titration Study to Assess the Effects of MK-8892 on Safety, Tolerability and Pharmacokinetics in Subjects With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: MK-8892;Drug: Placebo for MK-8892Merck Sharp & Dohme Corp.NULLCompleted18 Years70 YearsAll23Phase 1Bulgaria;Germany;Moldova, Republic of
3NCT01798849
(ClinicalTrials.gov)
March 15, 201322/2/2013A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)A Single Rising Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8892Pulmonary Arterial HypertensionDrug: MK-8892;Drug: Placebo for MK-8892Merck Sharp & Dohme Corp.NULLCompleted18 Years60 YearsMale25Phase 1Belgium